Estrogen and combined hormone therapy for women after genital malignancies: A review

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 49, Issue 10, 2004, Pages 837-848

  Levgur, Michael ^a,b  

^a MAIMONIDES MEDICAL CENTER   (United States)

^b Dept of Obstetrics and Gynecology ^*  (United States)

Author keywords

Estrogen replacement therapy; Female; Genital neoplasms; Hormone replacement therapy

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT;

ABDOMINAL HYSTERECTOMY; ADENOCARCINOMA; BREAST CANCER; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG SAFETY; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; ESTROGEN THERAPY; FEMALE GENITAL TRACT CANCER; FERTILIZATION IN VITRO; FOLLOW UP; GYNECOLOGY; HISTOLOGY; HORMONAL THERAPY; HUMAN; META ANALYSIS; OVARY CANCER; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENCE RISK; REVIEW; RISK ASSESSMENT; SALPINGOOOPHORECTOMY; SIDE EFFECT; UTERINE CERVIX CARCINOMA; VAGINA CANCER; VALIDATION PROCESS;

ADENOCARCINOMA; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CONTINUITY OF PATIENT CARE; DRUG THERAPY, COMBINATION; ESTROGEN REPLACEMENT THERAPY; FEMALE; GENITAL NEOPLASMS, FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; INCIDENCE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 7244242666     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Writing Group for the Women's Health Initiative Investigators: Risk and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 2002;288:321-333
2. Marchant DJ: Estrogen replacement therapy after breast cancer: Risks versus benefits. Cancer 1993;71:2169-2176
3. DiSaia PJ, Brewster WR: The choice of estrogen replacement therapy after a diagnosis of breast cancer. Ann Surg Oncol 1999;6:135-136
4. Holmberg L: Hormonal replacement therapy for women with a personal history of breast cancer? Ann Oncol 1996;7:655-656
5. Prichard KI: Hormone replacement in women with a history of breast cancer. Oncologist 2000;6:353-362
6. Varma TR: Sex steroids and cancer in older women. Drugs Aging 1992;2:174-195
7. Obermair A, Jirecek S, Leondolter S: Epidemiologic considerations on the significance of hormones in carcinogenesis. Gynakol Geburtshilf Rundsch 1998;38:73-79
8. Smith DC, Prentice R, Thompson DJ, et al: Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 1975;293:1164-1167
9. Persson I: The risk of endometrial and breast cancer after estrogen treatment: A review of epidemiological studies. Acta Obstet Gynecol Scand (suppl) 1985;130:59-66
10. Creasy GW, Kafrissen ME, Umalis D: Review of the endometrial effects of estrogens and progestins. Obstet Gynecol Surv 1992;47:654-678
11. Grady D, Gebretsadik T, Kerlikowske K, et al: Hormone replacement therapy and endometrial cancer risk: A meta-analysis. Obstet Gynecol 1995;85:304-313
12. Cramer DW, Knapp RC: Review of epidemiologic studies of endometrial cancer and exogenous estrogen. Obstet Gynecol 1979;54:521-526
13. Hammond CB, Jelovsek FR, Lee KL, et al: Effects of long term estrogen replacement therapy: II. Neoplasia. Am J Obstet Gynecol 1979;133:537-547
14. Jain MG, Rohan TE, Howe GR: Hormone replacement therapy and endometrial cancer in Ontario, Canada. J Clin Epidemiol 2000;53:385-391
15. Robboy SJ, Bradley R: Changing trends and prognostic features in endometrial cancer associated with exogenous estrogen therapy. Obstet Gynecol 1979;54:269-277
16. Schwartzbaum JA, Hulka BS, Fowler WC, et al: The influence of exogenous estrogen use on survival after diagnosis of endometrial cancer. Am J Epidemiol 1987;126:851-860
17. Jick SS, Walker AM, Jick H: Estrogens, progesterone and endometrial cancer. Epidemiology 1993;4:20-24
18. Orbo A, Sager G: How hazardous is the use of female steroid hormones? Tidsskr Nor Laegeforen 1997;117:972-976
19. Gambrell RD Jr: Hormones in the etiology and prevention of breast and endometrial cancer. South Med J 1984;77:1509-1515
20. Hill DA, Weiss NS, Beresford SA, et al: Continuous combined hormone replacement therapy and risk of endometrial cancer. Am J Obstet Gynecol 2000;183:1456-1461
21. Bosze P: Should estrogen replacement therapy by applied in women with genital and breast cancer? Orv Hetil 1995;136:465-472
22. Alexieva-Figusch J, Van Putten WL, Blankenstein MA, et al: The prognostic value and relationships of patient characteristics, estrogen, and progestin receptors, and the site of relapse in primary breast cancer. Cancer 1988;61:758-768
23. Hunt K, Vessey M, McPherson K, et al: Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynaecol 1987;94:620-635
24. Wren BG: Hormonal therapy following female genital tract cancer. Int J Gynecol Cancer 1994;4:217-224
25. Baker DP: Estrogen replacement therapy in patients with previous endometrial carcinoma. Compr Ther 1990;16:28-35
26. Creasman WT: HRT and women who have breast or endometrial cancer. J Epidemiol Biostat 1999;4:217-220
27. Creasman WT: Estrogen replacement therapy: Is previously treated cancer a contraindication? Obstet Gynecol 1991; 77:308-312
28. Creasman WT, Henderson D, Hinshaw W, et al: Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol 1986;67:326-330
29. Bryant GW: Administration of estrogens to patients with a previous diagnosis of endometrial adenocarcinoma. South Med J 1990;83:725-726
30. Suriano KA, Mchale M, Mclaren CE, et al: Estrogen replacement therapy in endometrial cancer patients: A matched control study. Obstet Gynecol 2001;97:550-560
31. Lee RB, Burke TW, Park RC: Estrogen replacement therapy following treatment for stage 1 endometrial cancer Gynecol Oncol 1990;36:189-191
32. Chapman JA, DiSaia PJ, Osann K, et al: Estrogen replacement in surgical stage I and II endometrial cancer survivors. Am J Obstet Gynecol 1996;175:1195-1200
33. Committee on Gynecologic Practice: Estrogen Replacement Therapy and Endometrial Cancer. Washington, DC, American College of Obstetricians and Gynecologists, 1993
34. Committee on Gynecologic Practice: Hormone Replacement Therapy in Women Treated for Endometrial Cancer. Washington, DC, American College of Obstetricians and Gynecologists, 2000
35. Gronroos M, Kangas L, Maenpaa J: Steroid receptors and response of ovarian cancer to hormones in vitro. Br J Obstet Gynaecol 1984;91:472-478
36. Ness RB, Grisso JA, Klapper J, et al: Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives: SHARE Study Group: Steroid hormones and reproduction. Am J Epidemiol 2000;152:233-241
37. The Cancer and Steroid Hormone Study of the CDC and the NICHHD. N Engl J Med 1987;316:650-655
38. Schlesselmann JJ: Cancer of the breast and reproductive tract in relation to use of oral contraceptives. Contraception 1989;40:1-38
39. Kimmig, Seehaus D, Scheidel P, et al: Hormonal replacement therapy and oral contraception: Risk of induction or reactivation of gynecologic malignancies. Gynaekol Geburtshilf Rundsch 1995;35:72-78
40. Gnagy S, Ming EE, Devesa SS, et al: Declining ovarian cancer rates in U.S. women in relation to parity and oral contraceptive use. Epidemiology 2000;11:102-105
41. Hankinson SE, Colditz GA, Hunter DJ, et al: A quantitative assessment of oral contraceptive use and risk of ovarian cancer. Obstet Gynecol 1992;80:708-714
42. Whittemore AS, Harris R, Itnyre J, et al: Characteristics relating to ovarian cancer in 12 US case-control studies: II. Invasive epithelial ovarian cancers in white women. Am J Epidemiol 1992;136:1184-1203
43. Denison U, Riegle-Keil M, Salzer H: Influence of adjuvant hormonal therapy on the whole female organism: Benefit versus potential injury. Gynaekol Geburtshilf Reundsch 1998;38:96-100
44. Kaufman DW, Kelly JP, Welch WR, et al: Non-contraceptive estrogen use and epithelial ovarian cancer. Am J Epidemiol 1989;130:1142-1151
45. Hempling RE, Wong C, Piver S, et al: Hormone replacement therapy as a risk factor for epithelial ovarian cancer: Results of a case-control study. Obstet Gynecol 1998;89:1012-1016
46. Persson I, Yuen J, Bergkvist L, et al: Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy: Long-term follow-up of a Swedish cohort. Int J Cancer 1996;67:327-332
47. Sittisomwong T, Suneja A, Kudelka AP, et al: Estrogen replacement therapy and ovarian cancer. Eur J Gynaecol Oncol 2000;21:348-354
48. Cramer D, Hutchison GB, Welch WR, et al: Determinants of ovarian cancer risk: I. Reproductive experiences and family history. J Natl Cancer Inst 1983;71:711-716
49. Risch HA: Estrogen replacement therapy and risk of epithelial ovarian cancer. Gynecol Oncol 1996;63:254-257
50. Purdie DM, Bain CJ, Siskind V, et al: Hormone replacement therapy and risk of epithelial ovarian cancer. Br J Cancer 1999;81:559-563
51. Riman T, Dickman PW, Nilsson S, et al: Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst 2002;94:497-504
52. Lacey JV, Mink PJ, Lubin A, et al: Menopausal hormone replacement therapy and risk of ovarian cancer. J Am Med Assoc 2002;288:334-341
53. Rodriguez C, Patel AV, Calle EE, et al: Esttogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. J Am Med Assoc 2001;285:1460-1465
54. Garg PP, Kerlikowske K, Subak L, et al: Hormone replacement therapy and the risk of epithelial ovarian carcinoma: A meta-analysis. Obstet Gynecol 1998;92:472-479
55. Coughlin SS, Giustozzi A, Smith SJ, et al: A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer. J Clin Epidemiol 2000;53:367-375
56. Negri E, Tzonou A, Beral V, et al: Hormonal therapy for menopause and ovarian cancer in collaborative reanalysis of European studies. Int J Cancer 1999;80:848-851
57. Helzisouer KJ, Alberg AJ, Gordon GB, et al: Serum gonadotropins and steroid hormones and the development of ovarian cancer. J Am Med Assoc 1995;274:1926-1930
58. Nieto JJ, Crow J, Sundaresan M, et al: Ovarian epithelial dysplasia in relation to ovulation induction and nulliparity. Gynecol Oncol 2001;82:344-349
59. Franco C, Coppola S, Prosperi Porta R, et al: Ovulation induction and the risk of ovarian tumors. Minerva Ginecol 2000;52:103-109
60. Klip H, Burger CW, Kenemans P, et al: Cancer risk associated with subfertility and ovulation induction: A review. Cancer Causes Control 2000;11:319-344
61. Gocze P, Krommer K, Csermely T, et al: Ovulation induction therapy and malignant ovarian cancer. Orv Hetil 2000;141:71-75
62. Dor J, Lerner-Geva L, Rabinovici J, et al: Cancer incidence in a cohort of infertile women who underwent in vitro fertilization. Fertil Steril 2002;77:324-327
63. Khalil MR: Epidemiology of ovarian cancer and female sex hormones. Ugeskr Laeger 2000;162:6395-6398
64. Eeles RA, Ran S, Witshaw E, et al: Hormone replacement therapy and survival after surgery for ovarian cancer. BMJ 1991;302:259-262
65. Ursic-Vrscaj M, Bebar S, Zakelj MP: Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: The effect on survival. Menopause 2001;8:70-75
66. Guidozzi F, Daponte A: Estrogen replacement therapy for ovarian carcinoma survivors: A randomized controlled trial. Cancer 1999;86:1013-1018
67. Burger CW, van Leeuwen FE, Scheele F, et al: Hormone replacement therapy in women treated for gynaecological malignancy. Maturitas 1999;32:69-76
68. Urdl W: Hormonal replacement therapy in patients with cervical and ovarian cancer. Gynaekol Geburtshilf Rundsch 1998;38:89-92
69. Palacios S: Cancer surveillance during HRT. Int J Fertil Menopausal Stud (suppl 2) 1994;39:93-98
70. Gadducci A, Fanucchi A, Cosio S, et al: Hormone replacement therapy and gynecological cancer. Anticancer Res 1997;17:3793-3798
71. Makar AP: Hormone therapy in epithelial ovarian cancer. Endocr Relat Cancer 2000;7:85-93
72. Atlas I, Gajewski W, Falkenberry S, et al: Absence of estrogen and progesterone receptors in glassy cell carcinoma of the cervix. Obstet Gynecol 1998;91:136-138
73. Martin JD, Hahnel R, McCartney AJ, et al: The influence of estrogen and progesterone receptors on survival in patients with carcinoma of the uterine cervix. Gynecol Oncol 1986;23:329-335
74. Ploch E: Hormonal replacement therapy in patients after cervical cancer treatment. Gynecol Oncol 1987;26:169-177
75. Schindler AE: Hormone replacement therapy (HRT) in women after genital cancer. Maturitas (suppl 1) 2002; 41:S105-S111